• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC TO-I filed by BlackRock Technology and Private Equity Term Trust

    6/9/25 4:16:52 PM ET
    $BTX
    Get the next $BTX alert in real time by email
    SC TO-I 1 d26156dsctoi.htm SC TO-I SC TO-I
     
     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE TO

     

     

    TENDER OFFER STATEMENT

    Under Section 14(d)(1) or 13(e)(1)

    of the Securities Exchange Act of 1934

     

     

    BlackRock Technology and Private Equity Term Trust

    (Name of Subject Company (Issuer))

    BlackRock Technology and Private Equity Term Trust

    (Names of Filing Person(s) (Issuer))

    Common Shares of Beneficial Interest, Par Value $0.001 per share

    (Title of Class of Securities)

    09260Q108

    (CUSIP Number of Class of Securities)

    John M. Perlowski

    BlackRock Technology and Private Equity Term Trust

    50 Hudson Yards

    New York, New York 10001

    (800) 882-0052

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications on Behalf of Filing Person(s))

     

     

    Copies to:

     

    Margery K. Neale, Esq.

    Elliot J. Gluck, Esq.

      Janey Ahn, Esq.
    Willkie Farr & Gallagher LLP   BlackRock Advisors, LLC
    787 Seventh Avenue   50 Hudson Yards
    New York, New York 10019   New York, New York 10001

     

     

    June 9, 2025

    (Date Tender Offer First Published, Sent or Given to Security Holders)

     

     

     

    ☐

    Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

    Check the appropriate boxes below to designate any transactions to which this statement relates:

     

      ☐

    third-party tender offer subject to Rule 14d-1

      ☒

    issuer tender offer subject to Rule 13e-4

      ☐

    going-private transaction subject to Rule 13e-3

      ☐

    amendment to Schedule 13D under Rule 13d-2

    Check the following box if the filing is a final amendment reporting the results of the tender offer. ☐

     

     
     


    Introductory Statement

    This Issuer Tender Offer Statement on Schedule TO relates to an offer by BlackRock Technology and Private Equity Term Trust (formerly, BlackRock Innovation and Growth Term Trust), a Maryland statutory trust (the “Fund”), to purchase 50% of its issued and outstanding common shares of beneficial interest, par value $0.001 per share (the “Shares”), in exchange for cash at a price equal to 99.5% of the net asset value (“NAV”) per Share (the “Purchase Price”) determined as of the close of the regular trading session of the New York Stock Exchange (the “NYSE”), the principal market on which the Shares are traded, on the next day the NAV is calculated after the offer expires (the “Pricing Date”), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated June 9, 2025 (the “Offer to Purchase”), and in the related Letter of Transmittal which are filed as Exhibits (a)(1)(i) and (a)(1)(ii), respectively, to this Schedule TO.

    This Issuer Tender Offer Statement on Schedule TO is being filed in satisfaction of the reporting requirements of Rule 13e-4(c)(2) promulgated under the Securities Exchange Act of 1934, as amended.

    The information set forth in the Offer to Purchase and the related Letter of Transmittal is incorporated herein by reference in answer to Item 1 through Item 9 and Item 11 of Schedule TO.

     

    Item 1.

    Summary Term Sheet

    The information set forth under “Summary Term Sheet” in the Offer to Purchase is incorporated herein by reference.

     

    Item 2.

    Subject Company Information

    (a) The name of the issuer is BlackRock Technology and Private Equity Term Trust, a non-diversified closed-end management investment company, organized as a Maryland statutory trust (the “Fund”). The principal executive offices of the Fund are located at 100 Bellevue Parkway, Wilmington, Delaware 19809. The telephone number of the Fund is (800) 882-0052.

    (b) The title of the securities being sought is common shares of beneficial interest, par value $0.001 per share. As of June 2, 2025, there were 213,338,148 Shares issued and outstanding.

    (c) The principal market in which the Shares are traded is the NYSE. For information on the high and low closing (as of the close of ordinary trading on the NYSE on the last day of each of the Fund’s fiscal quarters) market prices of the Shares in such principal market for each quarter for the past two calendar years, see Section 10, “Price Range of Shares” of the Offer to Purchase, which is incorporated herein by reference.

     

    Item 3.

    Identity and Background of Filing Person

    (a) The Fund is the filing person. BlackRock Advisors, LLC acts as the investment adviser for the Fund (the “Investment Advisor”). The Investment Advisor, located at 100 Bellevue Parkway, Wilmington, Delaware 19809, is a wholly owned subsidiary of BlackRock, Inc. The members of the Fund’s Board of Trustees are Cynthia L. Egan, Lorenzo A. Flores, Stayce D. Harris, J. Phillip Holloman, R. Glenn Hubbard, W. Carl Kester, Catherine A. Lynch, Arthur P. Steinmetz, Robert Fairbairn and John M. Perlowski (each, a “Trustee”). The principal executive officer and principal financial and accounting officer of the Fund are John M. Perlowski and Trent Walker, respectively. The Trustees and the executive officers of the Fund may be reached at the Fund’s business address and phone number set forth in Item 2(a) above. The information set forth in the Offer to Purchase under “Certain Information about the Fund” is incorporated herein by reference.

     

    - 2 -


    Item 4.

    Terms of the Transaction

    (a)(1) The following sections of the Offer to Purchase contain a description of the material terms of the transaction and are incorporated herein by reference:

     

      •  

    “Summary Term Sheet”

     

      •  

    “Price; Number of Shares”

     

      •  

    “Purpose of the Offer”

     

      •  

    “Plans or Proposals of the Fund”

     

      •  

    “Certain Conditions of the Offer”

     

      •  

    “Procedures for Tendering Shares for Purchase”

     

      •  

    “Withdrawal Rights”

     

      •  

    “Payment for Shares”

     

      •  

    “Source and Amount of Consideration”

     

      •  

    “Effects of the Offer; Consequences of Participation”

     

      •  

    “Interests of Trustees and Officers; Transactions and Arrangement Concerning the Shares”

     

      •  

    “Certain Information about the Fund”

     

      •  

    “Certain U.S. Federal Income Tax Consequences”

     

      •  

    “Amendments; Extensions of Repurchase Period; Termination”

     

      •  

    “Fees and Expenses”

    (a)(2) Not applicable.

    (b) The information set forth in the Offer to Purchase under “Interests of Trustees and Officers; Transactions and Arrangements Concerning the Shares” is incorporated herein by reference.

     

    Item 5.

    Past Contracts, Transactions, Negotiations and Agreements

    (e) The information set forth in the Offer to Purchase under “Purpose of the Offer,” “Plans or Proposals of the Fund,” “Interests of Trustees and Officers; Transactions and Arrangements Concerning the Shares” and “Certain Information about the Fund” is incorporated herein by reference.

     

    Item 6.

    Purposes of the Transaction and Plans or Proposals

    (a) The information set forth in the Offer to Purchase under “Purpose of the Offer” and “Plans or Proposals of the Fund” is incorporated herein by reference.

    (b) The information set forth in the Offer to Purchase under “Purpose of the Offer” is incorporated herein by reference.

    (c) The information set forth in the Offer to Purchase under “Purpose of the Offer” and “Plans or Proposals of the Fund” is incorporated herein by reference.

     

    Item 7.

    Source and Amount of Funds or Other Considerations

    (a) The information set forth in the Offer to Purchase under “Source and Amount of Consideration” is incorporated herein by reference.

     

    - 3 -


    (b) The information set forth in the Offer to Purchase under “Source and Amount of Consideration” is incorporated herein by reference.

    (d) The information set forth in the Offer to Purchase under “Source and Amount of Consideration” is incorporated herein by reference.

     

    Item 8.

    Interests in Securities of the Subject Company

    (a) The information set forth in the Offer to Purchase under “Interests of Trustees and Officers; Transactions and Arrangements Concerning the Shares” is incorporated herein by reference.

    (b) The information set forth in the Offer to Purchase under “Interests of Trustees and Officers; Transactions and Arrangements Concerning the Shares” is incorporated herein by reference.

     

    Item 9.

    Persons/Assets Retained, Employed, Compensated or Used

    (a) No persons have been directly or indirectly employed, retained, or are to be compensated by or on behalf of the Fund to make solicitations or recommendations in connection with the Offer to Purchase. The information set forth in the Offer to Purchase under “Fees and Expenses” is incorporated herein by reference.

     

    Item 10.

    Financial Statements

    (a) The audited annual financial statements of the Fund dated December 31, 2024 and the schedule of investments of the Fund dated December 31, 2024, both filed with the SEC on EDGAR on Form N-CSR on March 7, 2025, are incorporated by reference. The Fund will prepare and transmit to shareholders the audited annual financial statements of the Fund and the schedule of investments of the Fund within 60 days after the close of the period for which the report is being made, or as otherwise required by the Investment Company Act of 1940.

    (b) Not applicable.

     

    Item 11.

    Additional Information

    (a)(1) The information set forth in the Offer to Purchase under “Interests of Trustees and Officers; Transactions and Arrangements Concerning the Shares” is incorporated herein by reference.

    (a)(2) None.

    (a)(3) Not applicable.

    (a)(4) Not applicable.

    (a)(5) None.

    (c) Not applicable.

     

    - 4 -


    Item 12(a).

    Exhibits

     

    (a)(1)(i)

       Offer to Purchase, dated June 9, 2025, is filed herewith.

    (a)(1)(ii)

       Form of Letter of Transmittal is filed herewith.

    (a)(2)

       None.

    (a)(3)

       Not Applicable.

    (a)(4)

       Not Applicable.

    (a)(5)(i)

       Press release issued on January 21, 2025 is incorporated by reference to the Fund’s Schedule TO-C, as filed with the Commission on January 21, 2025.

    (a)(5)(ii)

       Press release issued on June 9, 2025, is filed herewith.

    (b)

       None.

    (d)(1)

       Form of Automatic Dividend Reinvestment Plan is incorporated by reference to Exhibit (e)  to Pre-Effective Amendment No. 1 to the Fund’s Registration Statement on Form N-2 (File No.  333-251526), as filed with the Commission on February 18, 2021.

    (d)(2)

       Form of Investment Management Agreement is incorporated by referenced to Exhibit (g)(1) to Pre-Effective Amendment No. 1 to the Fund’s Registration Statement on Form N-2, as filed with the Commission on February 17, 2021.

    (d)(3)

       Form of BlackRock Fixed-Income Complex Third Amended and Restated Deferred Compensation Plan is incorporated by reference to Pre-Effective Amendment No. 1 to the Registration Statement on Form N-2 of BlackRock Credit Strategies Fund (File No.  333-227456), as filed with the Commission on January 16, 2019.

    (d)(4)

       Discount Management Program Standstill Agreement among the Fund, Karpus Management, Inc. and BlackRock Advisors, LLC, dated May 3, 2024 is incorporated by referenced to Exhibit (d)(4) of the Fund’s Tender Offer Statement on Schedule TO (File No. 005-94016), as filed with the Commission on July 22, 2024.

    (d)(5)

       Standstill Agreement among the Fund, Saba Capital Management, L.P., and BlackRock Advisors, LLC, dated as of January 20, 2025, is filed herewith.

    (g)

       None.

    (h)

       None.

     

    Item 12(b).

    Filing Fees

    Filing Fee Exhibit

     

    Item 13.

    Information Required By Schedule 13E-3

    Not Applicable.

     

    - 5 -


    SIGNATURE

    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    BlackRock Technology and Private Equity Term Trust

    By:

     

    /s/ John M. Perlowski

     

    Name: John M. Perlowski

     

    Title:  President and Chief Executive Officer

     

    Dated: June 9, 2025

     

    - 6 -


    Exhibit Index

     

    Exhibit
    Number
     

    Description

    (a)(1)(i)   Offer to Purchase, dated June 9, 2025
    (a)(1)(ii)   Form of Letter of Transmittal
    (a)(5)(ii)   Press Release issued on June 9, 2025
    (d)(5)   Standstill Agreement
          Filing Fee Exhibit

     

    - 7 -

    Get the next $BTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTX

    DatePrice TargetRatingAnalyst
    12/29/2021$9.00Overweight
    Cantor Fitzgerald
    10/6/2021$20.00Buy
    Maxim Group
    More analyst ratings

    $BTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Minar Stephen Thomas claimed ownership of 1,967 shares (SEC Form 3)

      3 - BlackRock Technology & Private Equity Term Trust (0001836057) (Issuer)

      5/16/25 4:24:38 PM ET
      $BTX
    • SEC Form 3 filed by new insider Cicala Peter

      3 - Eterna Therapeutics Inc. (0000748592) (Issuer)

      2/16/24 5:30:35 PM ET
      $BTX
    • SEC Form 4 filed by Luther Sanjeev

      4 - Eterna Therapeutics Inc. (0000748592) (Issuer)

      1/3/24 5:02:56 PM ET
      $BTX

    $BTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting

      SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief

      5/31/22 7:30:00 AM ET
      $BTX
    • Amarin Announces Appointment of New Directors and Board Leadership Changes

      Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company's Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board's Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso "Chito" Zulueta to the Board, effective immediately. Ms. Enright and Mr. Zulueta will sta

      5/19/22 8:23:13 AM ET
      $AMRN
      $BTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors

      NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company's Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (serving as Audit Committee Chair), Medical Facilities Corporation (serving as Audit and Investment Committee Chair), and Dynatronics Corporation (serving on the Audit, Compensati

      1/20/22 7:30:00 AM ET
      $BTX

    $BTX
    SEC Filings

    See more
    • SEC Form SC TO-I filed by BlackRock Technology and Private Equity Term Trust

      SC TO-I - BlackRock Technology & Private Equity Term Trust (0001836057) (Subject)

      6/9/25 4:16:52 PM ET
      $BTX
    • SEC Form DEF 14A filed by BlackRock Technology and Private Equity Term Trust

      DEF 14A - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)

      5/22/25 5:04:16 PM ET
      $BTX
    • SEC Form DEFA14A filed by BlackRock Technology and Private Equity Term Trust

      DEFA14A - BlackRock Technology & Private Equity Term Trust (0001836057) (Filer)

      3/28/25 2:46:10 PM ET
      $BTX

    $BTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • BlackRock Technology and Private Equity Term Trust (BTX) Commences Tender Offer for up to 50% of outstanding common shares

      BlackRock Technology and Private Equity Term Trust (NYSE:BTX) (the "Fund") announced today the commencement, expiration and pricing dates of the previously announced offer to repurchase up to 50% of outstanding common shares at a price per share equal to 99.5% of the Fund's net asset value ("NAV") per common share as determined on the pricing date (the "Tender Offer"). The Fund's Board of Trustees approved the dates as detailed in the table below: Commencement Date Monday, June 9, 2025 Expiration Date and Time Tuesday, July 8, 2025 at 11:59 p.m. Eastern Time, unless otherwise extended Pricing Date Wednesday July 9, 2025 Shares of the Fund w

      6/9/25 4:31:00 PM ET
      $BTX
    • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

      Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 6/2/2025   Ex-Date- 6/13/2025   Record- 6/13/2025   Payable- 7/1/2025   National Funds    Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust*  BYM  $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN

      6/2/25 5:27:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

      Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital

      5/30/25 4:31:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • SEC Form SC 13G/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

      SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)

      1/31/24 7:05:56 AM ET
      $BTX
    • SEC Form SC 13G/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

      SC 13G/A - Eterna Therapeutics Inc. (0000748592) (Subject)

      1/19/24 10:31:54 AM ET
      $BTX
    • SEC Form SC 13D/A filed by Brooklyn ImmunoTherapeutics Inc. (Amendment)

      SC 13D/A - Eterna Therapeutics Inc. (0000748592) (Subject)

      12/22/23 12:05:20 PM ET
      $BTX

    $BTX
    Financials

    Live finance-specific insights

    See more
    • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

      Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 6/2/2025   Ex-Date- 6/13/2025   Record- 6/13/2025   Payable- 7/1/2025   National Funds    Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust*  BYM  $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN

      6/2/25 5:27:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

      Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital

      5/30/25 4:31:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable
    • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

      Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution   Declaration- 5/1/2025 Ex-Date- 5/15/2025 Record- 5/15/2025 Payable- 6/2/2025   Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municipal Incom

      5/1/25 7:59:00 PM ET
      $BBN
      $BCAT
      $BCX
      $BDJ
      Finance Companies
      Finance
      Finance/Investors Services
      Trusts Except Educational Religious and Charitable

    $BTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Brooklyn with a new price target

      Cantor Fitzgerald initiated coverage of Brooklyn with a rating of Overweight and set a new price target of $9.00

      12/29/21 7:03:49 AM ET
      $BTX
    • Maxim Group initiated coverage on Brooklyn ImmunoTherapeutics with a new price target

      Maxim Group initiated coverage of Brooklyn ImmunoTherapeutics with a rating of Buy and set a new price target of $20.00

      10/6/21 7:53:44 AM ET
      $BTX